Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

NCT ID: NCT03208660

Last Updated: 2019-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-07

Study Completion Date

2019-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fycompa

Participants diagnosed with epilepsy and treated with Fycompa

Fycompa

Intervention Type DRUG

Oral suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fycompa

Oral suspension

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perampanel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must have met all of the following criteria to be included in this study:

1. Diagnosis of epilepsy
2. Initiated treatment with Fycompa at any time after 01 Jan 2014
3. Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records (if required by an Institutional Review Board \[IRB\] or Independent Ethics Committee \[IEC\], or by regulatory authorities).

Exclusion Criteria

* Not applicable
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eisai Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Age Reversal & Neurology Clinic

Phoenix, Arizona, United States

Site Status

Bronislava Shafran, MD, PC

Phoenix, Arizona, United States

Site Status

Banner - University Medical Center Phoenix

Phoenix, Arizona, United States

Site Status

Arizona Neurological Institute

Sun City, Arizona, United States

Site Status

The University of Arizona Department of Neurology

Tucson, Arizona, United States

Site Status

Valley Children's Hospital

Madera, California, United States

Site Status

UC Davis Medical Center

Sacramento, California, United States

Site Status

Sutter Health

Sacramento, California, United States

Site Status

Colorado Springs Neurological Associates

Colorado Springs, Colorado, United States

Site Status

Boca Raton Regional Hospital

Boca Raton, Florida, United States

Site Status

Capernaum Medical Center

Lakeland, Florida, United States

Site Status

Nicklaus Children's Hospital

Miami, Florida, United States

Site Status

Nemours Children's Hospital

Orlando, Florida, United States

Site Status

Pediatric Neurology PA

Orlando, Florida, United States

Site Status

Doctors hospital of Sarasota

Sarasota, Florida, United States

Site Status

Intercoastal Medical Group

Sarasota, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

Meridian Clinical Research

Savannah, Georgia, United States

Site Status

Consultants in Epilepsy & Neurology PLLC

Boise, Idaho, United States

Site Status

Carle Foundation Hospital

Urbana, Illinois, United States

Site Status

Fort Wayne Neurological Center

Fort Wayne, Indiana, United States

Site Status

Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Wayne State University

Detroit, Michigan, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Spectrum Health System

Detroit, Michigan, United States

Site Status

Spectrum Health Medical Group

Grand Rapids, Michigan, United States

Site Status

Minnesota Epilepsy Group

Saint Paul, Minnesota, United States

Site Status

Northeast Regional Epilepsy Group

Hackensack, New Jersey, United States

Site Status

Icahn School of Medicine at Mount Sinai

Hartsdale, New York, United States

Site Status

Albert Einstein College of Medicine

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Northwell Health

New York, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Albert Einstein Medical Center

Philadelphia, Pennsylvania, United States

Site Status

Pennsylvania

Pittsburgh, Pennsylvania, United States

Site Status

Le Bonheur Children's Hospital - PIN

Memphis, Tennessee, United States

Site Status

Austin Epilepsy Center

Austin, Texas, United States

Site Status

University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Auburn Neurological Institute

Auburn, Washington, United States

Site Status

Northwest Neurology & Electrodiagnostic Center

Auburn, Washington, United States

Site Status

Seattle Children's Hospital - PIN

Seattle, Washington, United States

Site Status

MultiCare Institute for Research and Innovation

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Segal E, Wheless J, Moretz K, Penovich P, Patten A, Malhotra M. Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study. Seizure. 2022 May;98:87-94. doi: 10.1016/j.seizure.2022.02.011. Epub 2022 Feb 26.

Reference Type DERIVED
PMID: 35453064 (View on PubMed)

Segal E, Moretz K, Wheless J, Penovich P, Lancman M, Patten A, Malhotra M. PROVE-Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Interim Analysis in Pediatric Patients. J Child Neurol. 2022 Mar;37(4):256-267. doi: 10.1177/08830738211047665. Epub 2022 Jan 7.

Reference Type DERIVED
PMID: 34994582 (View on PubMed)

Wechsler RT, Wheless J, Zafar M, Huesmann GR, Lancman M, Segal E, Chez M, Aboumatar S, Patten A, Salah A, Malhotra M. PROVE: Retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy. Epilepsia Open. 2022 Jun;7(2):293-305. doi: 10.1002/epi4.12575. Epub 2022 Mar 20.

Reference Type DERIVED
PMID: 34942053 (View on PubMed)

Wheless J, Wechsler RT, Lancman M, Aboumatar S, Patten A, Malhotra M. Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study. Epilepsia Open. 2020 Dec 19;6(1):79-89. doi: 10.1002/epi4.12445. eCollection 2021 Mar.

Reference Type DERIVED
PMID: 33681651 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E2007-G000-506

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fycompa in Catamenial Epilepsy
NCT05201703 TERMINATED PHASE4
Fenfluramine for Adult Dravet Patients
NCT05560282 UNKNOWN PHASE3